Arcutis Biotherapeutics, Inc. Stock Analysis & AI Score
Arcutis Biotherapeutics, Inc. (ARQT) has an ST Score of 60.6 (B), driven by its Profitability (A+) and held back by its Valuation (F). Analysts rate it Buy with a $38.00 price target (+44.7% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Arcutis Biotherapeutics, Inc. (ARQT) has an ST Score of 60.6 (B), driven by its Profitability (A+) and held back by its Valuation (F). Analysts rate it Buy with a $38.00 price target (+44.7% upside).
- Strongest
- ProfitabilityA+
- Weakest
- ValuationF
All factor grades
- ProfitabilityA+
- GrowthA+
- MomentumB+
- ForecastB
- Financial StrengthD
- ValuationF
- Piotroski7/9
Contact
ARQT stock: frequently asked questions
What is ARQT's ST Score?
Arcutis Biotherapeutics, Inc. (ARQT) has an ST Score of 60.6 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ARQT a buy, hold, or sell?
Analysts rate ARQT a Buy, with a price target of $38.00 (+44.7% vs the current price). Our ST Score grades it B (60.6/100). The ST Score is a data-driven signal, not a recommendation.
What are ARQT's factor grades?
Valuation F, Profitability A+, Financial Strength D, Momentum B+, Growth A+, Forecast B.
What is ARQT's valuation grade?
Arcutis Biotherapeutics, Inc. (ARQT) earns a valuation grade of F, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ARQT's growth grade?
Arcutis Biotherapeutics, Inc. (ARQT) earns a growth grade of A+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ARQT's profitability grade?
Arcutis Biotherapeutics, Inc. (ARQT) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ARQT's financial strength grade?
Arcutis Biotherapeutics, Inc. (ARQT) earns a financial strength grade of D, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ARQT?
The average analyst price target for Arcutis Biotherapeutics, Inc. (ARQT) is $38.00 from 12 analysts, which is +44.7% versus the recent price of $26.27.
What is ARQT's Piotroski score?
Arcutis Biotherapeutics, Inc. (ARQT) has a Piotroski F-Score of 7 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.